Status:
COMPLETED
Sarcopenia in Head and Neck Cancer Patients Treated with Curative Hadrontherapy
Lead Sponsor:
CNAO National Center of Oncological Hadrontherapy
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The study focuses on the impact of sarcopenia on acute and late toxicities in head and neck tumor affected patients treated with particle therapy.
Detailed Description
To evaluate in HNC patients treated with particle therapy the impact of SP (measured by low skeletal muscle mass at the C3 vertebral body) on toxicity profile assessed according to NCI's Common Termin...
Eligibility Criteria
Inclusion
- All HNC histologies and stages
- Histological and/or radiological diagnosis of head and neck tumors
- The patient is able to give consent
- Definitive/postoperative treatment with curative intent
- Age \>18 years
- KPS\> 80
Exclusion
- Plurimetastiatic disease
- Palliative intent and re-irradiation treatments
- Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires
Key Trial Info
Start Date :
April 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06207708
Start Date
April 18 2023
End Date
January 31 2025
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CNAO
Pavia, Pv, Italy, 27100